EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Sumatriptan‐naproxen sodium in migraine: A review

Robyn-Jenia Wilcha iD, Shazia K Afridi, Piero Barbanti iD, Hans Christoph Diener iD, Tim Patrick Jürgens, Michel Lanteri-Minet, Christian Lucas, Jerôme Mawet, Xavier Moisset iD, Antonio Russo iD, Simona Sacco, Alexandra J Sinclair und 3 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16434 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Robyn-Jenia Wilcha und 14 weiteren Autor:innen. Beteiligte Einrichtung: Headache Group, NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, The Wolfson Sensory, Pain and Regeneration Research Centr…. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Migraine Disorders, Naproxen, Sumatriptan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORION PHARMA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Varied responses to acute migraine medications have been observed, with over one‐third (34.5%) of patients reporting insufficient headache relief. Sumatriptan‐naproxen sodium, a single, fixed‐dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg, was developed with the rationale of targeting multiple putative mechanisms involved in the pathogenesis of migraine to optimise acute migraine care.

Methods

A narrative review of clinical trials investigating sumatriptan‐naproxen sodium for both adults and adolescents was performed in March 2024.

Results

Across a total of 14 clinical trials in nine publications, sumatriptan‐naproxen sodium offered greater efficacy for 2‐h pain freedom (14/14) and sustained pain‐free response up to 24 h (13/14) compared with monotherapy and/or placebo for both adult and adolescent study participants with an acceptable and well‐tolerated adverse effect profile. Clinical trial data also demonstrates the effectiveness of sumatriptan‐naproxen sodium in participants with allodynia, probable migraine, menstrual‐related migraine and those with poor responses to acute, non‐specific, migraine medication.

Conclusions

Multi‐mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan‐naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen‐sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalMigraine DisordersNaproxenSumatriptanVasoconstrictor AgentsAdolescentAdultFemaleMaleYoung AdultAcute DiseaseClinical Trials as TopicDrug CombinationsTreatment OutcomeHumans

Stichwörter der Autor:innen

acute migraine attackcombination tabletpharmacokineticssumatriptan‐naproxen sodiumtreatment

Substanzen

Anti-Inflammatory Agents, Non-SteroidalDrug CombinationsNaproxenSumatriptansumatriptan-naproxenVasoconstrictor Agents

Autor:innen und Institutionen

  • Headache Group, NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, The Wolfson Sensory, Pain and Regeneration Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's Colleg…
  • Neurology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Headache and Pain Unit, IRCCS San Raffaele Roma, Rome, Italy.
  • San Raffaele University, Rome, Italy.
  • Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Medical Faculty of the University Duisburg-Essen, Essen, Germany.
  • Neurologisches Zentrum, Neurologische Klinik, KMG Klinikum Güstrow, Güstrow, Germany.

ORCID-Profile: Robyn-Jenia Wilcha, Piero Barbanti, Hans Christoph Diener, Xavier Moisset, Antonio Russo, Cristina Tassorelli, Peter J Goadsby

Förderung

  • ORION PHARMA

Zitieren

APA

Wilcha, R. J., Afridi, S. K., Barbanti, P., Diener, H. C., Jürgens, T. P., Lanteri-Minet, M., Lucas, C., Mawet, J., Moisset, X., Russo, A., Sacco, S., Sinclair, A. J., Sumelahti, M. L., Tassorelli, C., & Goadsby, P. J. (2024). Sumatriptan‐naproxen sodium in migraine: A review. European Journal of Neurology. https://doi.org/10.1111/ene.16434

Vancouver

Wilcha RJ, Afridi SK, Barbanti P, Diener HC, Jürgens TP, Lanteri-Minet M, et al. Sumatriptan‐naproxen sodium in migraine: A review. European Journal of Neurology. 2024. doi:10.1111/ene.16434

BibTeX
@article{Wilcha2024,
  author = {Wilcha, Robyn-Jenia and Afridi, Shazia K and Barbanti, Piero and Diener, Hans Christoph and Jürgens, Tim Patrick and Lanteri-Minet, Michel and Lucas, Christian and Mawet, Jerôme and Moisset, Xavier and Russo, Antonio and Sacco, Simona and Sinclair, Alexandra J and Sumelahti, Marja-Liisa and Tassorelli, Cristina and Goadsby, Peter J},
  title = {Sumatriptan‐naproxen sodium in migraine: A review},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16434}
}
Kostenlos starten →